mortality at 30 days, with one death in a patient with functional MR after 5.8 years and a degenerative MR patient after 3.2 years. There were no strokes with an average follow-up of 2.4AE1.8 years. There were sustained improvements in New York Heart Association class (from 2.8 AE 0.6 to 1.6 AE 0.5, p <0.001) and MR grade (from 3.5 AE 0.9 to 0.4 AE 0.5, p <0.001) at follow-up. Conclusions: In this large single center experience, no patient required urgent cardiac surgery for failed MitraClip procedure. Mitral valve repair rate in patients with degenerative MR was high, and surgical options were preserved in the remaining patients. Overall, cardiac surgical outcomes were excellent.
Background:
In primary or degenerative mitral regurgitation (DMR), the mitral valve (MV) leaflets are structurally abnormal. The MitraClip device is the only percutaneous leaflet-based therapy evaluated by both randomized and registry-based studies utilizing core lab evaluation of patients with moderate to severe or severe (! 3+) DMR. Functional MR has been separately and previously evaluated. Methods: One-year data from the EVEREST II studies were analyzed for 509 patients with severe baseline DMR, including 447 treated with MitraClip and 62 who underwent a first MV surgery. Results: MV leaflet pathologies of prolapse and flail were well-represented. Compared to surgical candidates, high-risk DMR patients had STS mortality risk scores of !12%, or surgeon assessment of excessive risk based on pre-specified factors. They were older, more frequently had serious baseline co-morbidities, and had more severe functional impairment than DMR patients in the RCT (Table 1) . Implant rates were consistently high across MitraClip DMR cohorts. Safety outcomes reflected patient risk status. Lower-risk DMR patients who underwent MV surgery had more complete MR reduction and greater improvement in LV volumes than did lower-risk DMR patients who received MitraClip. Despite their burden of co-morbidities, a large proportion of high-risk DMR patients who received MitraClip achieved and maintained MR reduction to 2+ or less and did not undergo MV surgery. Background: Following CE approval in 2008, percutaneous mitral valve repair with the MitraClip system (Abbott) has entered clinical practice in Europe, where it is predominantly used to treat patients (pts) at high surgical risk. We sought to assess, and elucidate the interrelation of, baseline echocardiographic variables predictive of acute procedural failure in such pts. Methods: The first 300 consecutive pts (75 AE 9 years, 190 men [63%]) who underwent MitraClip therapy for grade 3+/4+ mitral regurgitation (MR) at our institution comprised the study cohort. All pts were adjudicated by heart team consensus as not amenable to surgery. Procedural failure, defined as discharge MR !3+, was encountered in 32 patients (10.7%), with 11 aborted procedures (no clip implanted) and 21 clip failures (MR !3+ despite clip implantation). Results: Exact logistic regression analysis identified effective regurgitant orifice area (EROA), mitral valve orifice area (MVOA), mean transmitral pressure gradient (TPG), and MR severity (not quantified via EROA) as predictive of failure. Classification tree analysis (Figure) revealed EROA as the variable with highest discriminatory power, followed by MVOA, TPG and MR severity. The highest incidence of clip failures occurred in pts with EROA >0.71cm2, highest incidence of aborted procedures in pts with MVOA 3.0cm2 and TPG !4mmHg.
Conclusions: Baseline echocardiographic variables differentially impact the procedural outcome of MitraClip therapy. Classification tree analysis clarifies their interrelationship and may help to reduce the procedural failure rate. Background: Impaired renal function (RF) is strongly associated with poor outcome in patients (pts) with chronic heart failure (HF). We sought to assess the acute effect of MitraClip therapy (MC) on RF and its impact on mortality and HF rehospitalization. Methods: In a retrospective analysis of 306 surgical high-risk pts (74.4 AE 8.7 years, 197 men [64.4%]) with !grade 3+ mitral regurgitation (MR) treated by MC, we calculated glomerular filtration rate (GFR) at baseline (BL) and discharge from creatinine levels (CKD-EPI formula). GFR was converted into the 5 Kidney Disease Outcomes Quality Initiative (KDOQI) stages. Pts were followed for 16 AE 11 (range, 0.3-41) months. Results: MC acutely improved RF (DKDOQI <0) in 82 pts (27%) and worsened RF (DKDOQI >0) in 31 pts (10%), with no change in 63% of pts. Overall, survival was 
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